Dec 19, 2012 by Brian Orelli, PhDAmgen to Pay $762 Million to Settle Marketing InvestigationsThe plea resolves criminal and civil suit that's over a year old.
Dec 14, 2012 by Brian Orelli, PhDThe Good News Is This Can Only Go on for 5 YearsAmarin fails to get an FDA decision about NCE status -- again.
Dec 14, 2012 by Brian Orelli, PhDIt's Hard to Make Money When FDA Approvals Are Priced InARIAD slumps 14% after getting its leukemia drug Iclusig approved.
Dec 14, 2012 by Brian Orelli, PhD3 Investment Lessons From Biotech's 2012 SuccessesThe only way to repeat success is to learn why they happened.
Dec 14, 2012 by Brian Orelli, PhD3 Investment Lessons From Biotech's 2012 FailuresAs they say, "fool me once, shame on you. Fool me twice, shame on me."
Dec 13, 2012 by Brian Orelli, PhDGood, Not Great, Isn't Good EnoughAstraZeneca and Rigel's fostamatinib fails to beat Abbott's Humira.
Dec 12, 2012 by Brian Orelli, PhD1 Risk Threatening Eli LillyWith today's news on solanezumab, Eli Lilly may be falling into a trap.
Dec 12, 2012 by Brian Orelli, PhDDividend vs. Cash? Take the CashSpectrum Pharmaceuticals issues a special dividend.
Dec 12, 2012 by Brian Orelli, PhDGilead Needs to Ask, "YMI Buying This Biotech?"Gilead buys YM Biociences for its myelofibrosis drug, but has one of its own.
Dec 10, 2012 by Brian Orelli, PhDSolid Data, More Studies NeededCelldex's CDX-011 looks good, but likely still needs another trial for approval
Dec 7, 2012 by Brian Orelli, PhDAmarin: "You Just Have to Get on With It"With no buyer in sight, Amarin plans to hire a sales force to launch Vascepa.
Dec 6, 2012 by Brian Orelli, PhDPositive Clinical Trial! Stock Price? Not So Much.Chelsea announces a positive trial, but the endpoint isn't what the FDA wants.
Dec 3, 2012 by Brian Orelli, PhDWhy Abbott's Falling Dividend Isn't a ConcernAbbott's dividend is falling, but it's offset by Abbvie's big payout.
Nov 30, 2012 by Brian Orelli, PhDWill Sarepta Receive Accelerated Approval?It's clear the company has a lot of convincing to do.
Nov 30, 2012 by Brian Orelli, PhDA Commercial-Stage Biotech at Last Exelixis gains FDA approval for Cometriq in thyroid cancer, but it's the other indications that count.
Nov 29, 2012 by Brian Orelli, PhDFDA Rejection. EU Withdrawal. Set and Match?ARIAD and Merck's ridaforolimus might still have life.
Nov 29, 2012 by Brian Orelli, PhDAbbott Labs Gets a MakeoverWhat will Abbott Labs look like post spinoff?
Nov 28, 2012 by Brian Orelli, PhDFirst to Phase 3! Whoopee?Investors yawn at Gilead's phase 3 data for its interferon-free hep C program.
